poisar

Stocks · News reference

Zevra Therapeutics Receives Negative Opinion From EMA CHMP On Its Marketing Authorization Application For Arimoclomol For The Treatment Of Niemann-Pick Disease Type C

Jul 24, 2026, 11:33 AMBenzinga Newsdesk

Under European regulatory procedures, the Company plans to request a re-examination of the CHMP opinion and submit a detailed explanation outlining the basis for the request."While the review did not result in the

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

ZVRA
Source
benzinga
Observed
Jul 24, 2026, 11:33 AM
Checked
Jul 24, 2026, 11:33 AM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading